Charles Henderson Speaks to Atlanta Health Care Professionals
Thursday was an exciting night for the President of Piedmont Cancer Institute's Dr. Charles Henderson.
An expert orator and knowledgeable pharmaceutical consumer, Dr. Henderson was invited to speak on behalf of AMGEN’s proven clinical drug therapy for skeletal related events (SREs), XGEVA. As the first bone targeted therapy approved for cancer patients in almost ten years, XGEVA is designated to the prevention of SREs in patients with bone metastases from solid tumors.
Bone metastasis is one of the most frequent causes of pain in people with cancer. When a cancer spreads to the bone, it can make the bones weaker and even cause them to break. The approval of this drug illustrates the endless possibilities of medical advancements and shows what can happen when scientific innovation is brought together with opportunity and commitment.
Georgia Eboka, RN said, “The information Dr. Henderson shared with us tonight will be very beneficial to the patients I help treat. All health care providers should learn about the new effects of XGEVA.”
Dr Henderson has spoken at many national events, and has been recognized as an Oral Presenter by the ASH Plenary Session. His 30+ years of experience in Medical Oncology have given him the knowledge and expertise to be able to speak publically on one of the most dynamic topics in healthcare.
For the next few months, Dr. Henderson will continue educating health professionals on the importance and patient benefits of using the latest, most proficient drugs in the industry.